Achieve Life Sciences Advances Cytisinicline to Combat Growing Nicotine Dependency Crisis

Achieve Life Sciences Advances Cytisinicline Development Amidst Growing Nicotine Dependency Crisis

Achieve Life Sciences, Inc., a late-stage specialty pharmaceutical company, is making significant strides in the fight against nicotine dependence with its innovative product, cytisinicline. As the company prepares for one-on-one meetings during the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, CEO Rick Stewart and senior management will share insights into the late-stage program for cytisinicline, which is poised to address the urgent need for effective smoking and vaping cessation solutions. With the increasing prevalence of nicotine addiction among U.S. adults—approximately 29 million currently smoke combustible cigarettes and around 17 million use e-cigarettes—the urgency for new treatments has never been clearer.

The recent acceptance of Achieve’s New Drug Application (NDA) for cytisinicline by the U.S. Food and Drug Administration (FDA) marks a pivotal moment for the company. With a Prescription Drug User Fee Act (PDUFA) date set for June 20, 2026, the application is supported by data from two completed Phase 3 studies and a safety study that collectively demonstrate cytisinicline’s efficacy in treating nicotine dependence in adults. This is particularly relevant given the alarming statistic that over eight million people die annually from tobacco-related causes worldwide, with nearly half a million of those deaths occurring in the United States. The focus on cytisinicline is not only a response to the current smoking epidemic but also addresses the rising trend of vaping among youth, where 1.6 million middle and high school students reported e-cigarette usage in 2024.

Cytisinicline, a plant-based alkaloid, exhibits a unique mechanism by binding to nicotinic acetylcholine receptors in the brain, which may help mitigate the cravings associated with nicotine addiction. Achieve has also successfully completed a Phase 2 study focused on vaping cessation, coupled with a productive end-of-Phase 2 meeting with the FDA to discuss this indication. Given that there are currently no FDA-approved treatments specifically for e-cigarette cessation, Achieve’s work with cytisinicline is set to fill a critical gap in the market and potentially change the landscape of nicotine addiction treatment.

In other developments, Achieve Life Sciences invites interested parties to connect with its Investor Relations team for scheduling meetings during the upcoming conference. The commitment to addressing nicotine dependence through innovative therapies places Achieve at the forefront of public health efforts aimed at reducing tobacco-related morbidity and mortality, reinforcing the company's role as a key player in the pharmaceutical landscape.